Some three months after the company first disclosed partnership interest, CRISPR Therapeutics board member and SR One CEO Simeon George, M.D., says it’s “still early days” for sealing new deals. George’s level-setting brings back down to earth the speed at which CRISPR Tx is likely to land suitors for backburner pipeline assets even as CEO […]
